KEAMANAN PENGGUNAAN OBAT PADA KEHAMILAN DI RUMAH SAKIT SWASTA YOGYAKARTA

Authors

  • Chynthia Pradiftha Sari Universitas Islam Indonesia
  • Suci Hanifah Prodi Studi Farmasi, Jurusan Farmasi, Universitas Islam Indonesia, Yogyakarta
  • Yosi Febrianti Prodi Studi Farmasi, Jurusan Farmasi, Universitas Islam Indonesia, Yogyakarta
  • Azmi Fahma Sari Prodi Studi Farmasi, Jurusan Farmasi, Universitas Islam Indonesia, Yogyakarta
  • Pipit Dwirahmania Prodi Studi Farmasi, Jurusan Farmasi, Universitas Islam Indonesia, Yogyakarta

DOI:

https://doi.org/10.36387/jiis.v10i2.2485

Keywords:

Drug safety, FDA category, Pregnancy, Hospital

Abstract

Pregnancy is a special physiological condition in which the use of medication is often unavoidable. However, the risks of teratogenicity and drug safety require careful evaluation to minimize risks to both mother and fetus. This study aims to evaluate the safety of drug use based on FDA (Food and Drug Administration) categories in pregnant inpatients at a private hospital in Yogyakarta. The study uses a descriptive observational method with a cross- sectional design, analyzing 141 inpatient medical records from 2022. The analyzed data includes patient demographics, diagnoses, drug safety, and dosages. Inclusion criteria were pregnant inpatients treated with or without pregnancy emergencies; exclusion criteria were patients giving birth or experiencing abortion. Descriptive results (using Microsoft Excel) showed most pregnant inpatients were aged 20-35 years (80.14%), hospitalized during the first trimester (49.65%), had no comorbidities (90.07%), no emergency pregnancy conditions (82.27%), and a length of stay under 4 days (72.34%). The most common diagnosis was hyperemesis gravidarum (41.84%), with predominant use of multivitamins (16.18%) and antiemetics (14.91%). The safety of drugs in inpatients was categorized as A (18.80%), B (34.34%), C (36.86%), D (2.26%), and N (6.77%), with appropriate dosage usage (96,30%). The study concludes that drug use was dominated by category C, and no use of category X drugs was found. The most used drugs were folic acid multivitamins and iron supplements for increasing blood levels.

References

Al-Hamimi, J. Z., & Al Balushi, K. A. (2016). Patterns of prescription drugs use among pregnant women at Sultan Qaboos University Hospital and Sultan Qaboos University Hospital Family and Community Medicine Clinic, Oman. J Pharm Bioallied Sci, 8(4), 309-313. https://doi.org/10.4103/0975-7406.199347

Alema, N. M., Semagn, G., Melesse, S., Araya, E. M., Gebremedhin, H., Demsie, D. G., Asgedom, S. W., & Weldekidan, E. (2020). Patterns and determinants of prescribed drug use among pregnant women in Adigrat general hospital, northern Ethiopia: a cross-sectional study. BMC Pregnancy Childbirth, 20(1), 624. https://doi.org/10.1186/s12884-020-03327-7

Andersen, S. L. (2025). An update on the safety of antithyroid drugs in pregnancy: the power of real-world data. Expert Opinion on Drug Safety, 1-11. https://doi.org/10.1080/14740338.2025.2564073

Atkinson, A. J., Jr. (2018). Augmented renal clearance. Transl Clin Pharmacol, 26(3), 111-114. https://doi.org/10.12793/tcp.2018.26.3.111

Attali, E., & Yogev, Y. (2021). The impact of advanced maternal age on pregnancy outcome. Best Practice & Research Clinical Obstetrics & Gynaecology, 70, 2-9. https://doi.org/https://doi.org/10.1016/j.bpobgyn.2020.06.006

Balon, M., Tessier, S., Damase-Michel, C., Cottin, J., Lambert, A., Thompson, M. A., Benevent, J., & Lacroix, I. (2023). Adverse drug reactions in pregnant women: Do they differ from those in non-pregnant women of childbearing age? Therapie, 78(2), 165-173. https://doi.org/10.1016/j.therap.2022.11.005

Bandoli, G., Palmsten, K., Forbess Smith, C. J., & Chambers, C. D. (2017). A Review of Systemic Corticosteroid Use in Pregnancy and the Risk of Select Pregnancy and Birth Outcomes. Rheum Dis Clin North Am, 43(3), 489-502. https://doi.org/10.1016/j.rdc.2017.04.013

Feghali, M., Venkataramanan, R., & Caritis, S. (2015). Pharmacokinetics of drugs in pregnancy. Semin Perinatol 39(7), 512-519.

https://doi.org/10.1053/j.semperi.2015.08.003

Food, U. S., & Administration, D. (2019, August 1, 2019). FDA issues final rule on changes to pregnancy and lactation labeling information for prescription drug and biological products. U.S. Food and Drug Administration. https://www.fda.gov/drugs/labeling/pregnancy-and-lactation-labeling-drugs- final-rule

Jansen, L. A. W., Nijsten, K., Limpens, J., van Eekelen, R., Koot, M. H., Grooten, I. J., Roseboom, T. J., & Painter, R. C. (2023). Perinatal outcomes of infants born to mothers with hyperemesis gravidarum: A systematic review and meta-analysis. Eur J Obstet Gynecol Reprod Biol, 284, 30-51.

https://doi.org/10.1016/j.ejogrb.2023.03.004

Kemp, M. W., Newnham, J. P., Challis, J. G., Jobe, A. H., & Stock, S. J. (2016). The clinical use of corticosteroids in pregnancy. Hum Reprod Update, 22(2), 240-259. https://doi.org/10.1093/humupd/dmv047

Kim, J. H., & Scialli, A. R. (2011). Thalidomide: the tragedy of birth defects and the effective treatment of disease. Toxicol Sci, 122(1), 1-6. https://doi.org/10.1093/toxsci/kfr088

McParlin, C., O'Donnell, A., Robson, S. C., Beyer, F., Moloney, E., Bryant, A., Bradley, J., Muirhead, C. R., Nelson-Piercy, C., Newbury-Birch, D., Norman, J., Shaw, C., Simpson, E., Swallow, B., Yates, L., & Vale, L. (2016). Treatments for Hyperemesis Gravidarum and Nausea and Vomiting in Pregnancy: A Systematic Review. Jama, 316(13), 1392-1401. https://doi.org/10.1001/jama.2016.14337

Neiger, R. (2017). Long-Term Effects of Pregnancy Complications on Maternal Health: A Review. J Clin Med, 6(8). https://doi.org/10.3390/jcm6080076

Nguyen, C. T., Sasso, E. B., Barton, L., & Mestman, J. H. (2018). Graves' hyperthyroidism in pregnancy: a clinical review. Clin Diabetes Endocrinol, 4, 4.

https://doi.org/10.1186/s40842-018-0054-7

Patel, S., Patel, K., Patel, H., Gajjar, U., Deshpande, S., & Mathuria, A. (2021). Evaluation of Usage of Drugs in Pregnancy at Private Hospitals. Indian Journal of Pharmacy Practice, 14, 259-267. https://doi.org/10.5530/ijopp.14.4.53

Porgador, O., Sheiner, E., Pariente, G., & Wainstock, T. (2024). Pregnancy outcomes by hyperemesis gravidarum severity and time of diagnosis: A retrospective cohort study. Int Gynaecol Obstet, 167(3), 1075-1083. https://doi.org/10.1002/ijgo.15760

Sarayani, A., Albogami, Y., Thai, T. N., Smolinski, N. E., Patel, P., Wang, Y., Nduaguba, S., Rasmussen, S. A., & Winterstein, A. G. (2022). Prenatal exposure to teratogenic medications in the era of Risk Evaluation and Mitigation Strategies. American Journal of Obstetrics and Gynecology, 227(2), 263.e261-263.e238. https://doi.org/https://doi.org/10.1016/j.ajog.2022.01.004

Sukumaran, D., Cherian, A. G., Das, S., Winston, A. B., Kumar, A., & Shanthi Fx, M. (2016). Drug Prescribing Pattern During Intranatal Period in a Secondary Care Hospital in South India: A Retrospective Study. J Prim Care Community Health, 7(2), 113-117. https://doi.org/10.1177/2150131915627768

Weld, E. D., Bailey, T. C., & Waitt, C. (2022). Ethical issues in therapeutic use and research in pregnant and breastfeeding women. Br J Clin Pharmacol, 88(1), 7-21

Downloads

Published

2025-10-31

Issue

Vol. 10 No. 2 (2025): Jurnal Ilmiah Ibnu Sina

Section

Article

License

Copyright (c) 2025 JIIS (Jurnal Ilmiah Ibnu Sina): Ilmu Farmasi dan Kesehatan

Creative Commons License

This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.

How to Cite

KEAMANAN PENGGUNAAN OBAT PADA KEHAMILAN DI RUMAH SAKIT SWASTA YOGYAKARTA. (2025). JIIS (Jurnal Ilmiah Ibnu Sina): Ilmu Farmasi Dan Kesehatan, 10(2), 39-49. https://doi.org/10.36387/jiis.v10i2.2485

Similar Articles

71-80 of 116

You may also start an advanced similarity search for this article.